|
RA Patients n (%) |
Controls n (%) |
Statistical Analyses | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Total (n=81) |
ACPA+ (n=51) |
ACPA- (n=30) |
(n=40) |
Patients vs controls |
ACPA+ pts vs controls |
ACPA- pts vs controls |
ACPA+ pts vs ACPA- pts vs controls |
ACPA+ pts vs ACPA- pts |
ACPA+ GG/TT pts vs ACPA- GG/TT pts |
|
| HLA-DRB1 alleles | ||||||||||
| Subjects with R allele(s) | 55 (67.9%) |
41 (80.4%) |
14 (46.7%) |
15 (37.5%) |
p=.002 (MWW) τ=.269, p=.003 OR=3.5, p=.002 |
p=.00 (MWW) τ=.438, p=.00 OR=6.8, p=.0001 |
p=.444 (MWW) | p=.00 (K-W) τ=.364, p=.00 |
p=.002 (MWW) τ=.349, p=.002 OR=4.7, p=.002 |
p=.005 (MWW) τ=.392, p=.005 |
| Subjects with P allele(s) | 27 (33.3%) |
15 (29.4%) |
12 (40%) |
30 (75%) |
p=.00 (MWW) τ=.281, p=.002 OR=6, p<.0001 |
p=.00 (MWW) τ=.453, p=.00 OR=7.2, p<.0001 |
p=.003 (MWW) τ=.354, p=.003 OR=4.5, p=.004 |
p=.00 (K-W) τ=.362, p=.00 |
p=.332 (MWW) | p=.793 (MWW) |
| R alleles frequency | 79 (48.7%) |
59 (57.8%) |
20 (33.3%) |
16 (20%) |
p=.00 (MWW) τ=.309, p=.00 |
p=.00 (MWW) τ=.474, p=.00 |
p=.208 (MWW) | p=.00 (K-W) τ=.383, p=.00 |
p=.007 (MWW) τ=.286, p=.007 |
p=.011 (MWW) τ=.331, p=.011 |
| P alleles frequency | 33 (20.4%) |
17 (16.7%) |
16 (26.7%) |
34 (42.5%) |
p=.00 (MWW) τ=.278, p=.002 |
p=.00 (MWW) τ=.429, p=.00 |
p=.023 (MWW) τ=.264, p=.023 |
p=.00 (K-W) τ=.333, p=.00 |
p=.242 (MWW) | p=.667 (MWW) |
| HLA-DRB1 genotypes | ||||||||||
| RR | 24 (29.6%) |
18 (35.3%) |
6 (20%) |
1 (2.5%) |
p=.001 (MWW) τ=.239, p=.004 |
p=.00 (MWW) τ=.350, p=.00 |
p=.061 (MWW) | p=.002 (K-W) τ=.246, p=.001 |
p=.644 (MWW) | p=.978 (MWW) |
| RN | 21 (25.9%) |
15 (29.4%) |
6 (20%) |
4 (10%) |
||||||
| RP | 10 (12.3%) |
8 (15.7%) |
2 (6.7%) |
10 (25%) |
||||||
| NN | 9 (11.1%) |
3 (5.9%) |
6 (20%) |
5 (12.5%) |
||||||
| PN | 11 (13.6%) |
5 (9.8%) |
6 (20%) |
16 (40%) |
||||||
| PP | 6 (7.4%) |
2 (3.9%) |
4 (13.3%) |
4 (10%) |
||||||